UBS Maintains Buy on Johnson & Johnson, Raises Price Target to $320

Benzinga Newsdesk www.benzinga.com Positive 89.2%

Neg 0% Neu 0% Pos 89.2%

UBS analyst Michael Yee maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $280 to $320.